B1

to a component of an amyloid deposit in the patient, wherein the isotype of the antibody is human IgG1.

REMARKS

Claims 1-12, 14-15, and 19-30 are pending. Claims 1-12, 14-15, 19-23, and 26 are under consideration, claims 13 and 16-18 having been canceled and claims 24-25 and 27-30 having been withdrawn from consideration. Claim 1 has been amended. Support for the amendment can be found throughout the specification, *e.g.*, claim 17 as filed. The amendment to claim 1 adds no new matter.

Applicant elects Group I, claims 1-23 and 26. Applicant elects the following species: 1B, human antibodies; 2B, monoclonal antibodies; and 3A, IgG1 antibodies. Claims 1-11, 14-15, 19-23, and 26 read on species 1B, human antibodies. Claims 1-12, 15, 19-23, and 26 read on species 2B, monoclonal antibodies. Claims 1-12, 14-15, 19-23, and 26 read on 3A, IgG1 antibodies. Applicant acknowledges claim 1 is generic.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: (650) 326-2422
RLC
PA 3249988 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

1. (Amended) A method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient, wherein the isotype of the antibody is human IgG1.